Phase 3 Results Show Daraxonrasib Significantly Improves Survival in Previously Treated Pancreatic Cancer

(RTTNews) – Revolution Medicines, Inc. (RVMD) announced pivotal Phase 3 results from its RASolute 302 trial of Daraxonrasib in patients with previously treated metastatic pancreatic ductal adenocarcinoma. The data, presented at a late‑breaking plenary session at ASCO 2026 and published simultaneously in the New England Journal of Medicine, demonstrated unprecedented survival gains compared to standard chemotherapy.

Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers, often diagnosed at advanced stages and exhibiting resistance to conventional therapies. In the global, randomized trial involving 500 patients, once‑daily oral Daraxonrasib reduced the risk of death by 60% versus chemotherapy, doubling median overall survival to 12.4 months from 6.7 months. Progression‑free survival also improved markedly, and objective response rates were more than three times higher than with standard treatment.

Daraxonrasib exhibited a manageable safety profile, with fewer treatment discontinuations and lower rates of severe side effects than chemotherapy. Patients reported slower pain progression, improved global health status, and enhanced quality of life, underscoring the therapy’s potential to benefit both survival and daily functioning.

Mark Goldsmith, M.D., Ph.D., CEO of Revolution Medicines, noted: “These results significantly raise the survival benchmark in one of the most lethal cancers” and stated that they “firmly support Daraxonrasib as the new standard of care for previously treated metastatic pancreatic cancer.” Daraxonrasib is the first agent in a novel class of RAS(ON) multi‑selective inhibitors targeting a broad spectrum of RAS variants. The company plans to submit the trial data to global regulators, including the FDA, under a priority review pathway.

We reported on May 29, 2026 when RVMD traded at $154.63. The stock has traded between $34.00 and $158.13 over the past year. It closed at $157.48 on May 29, 2026, up 1.84%, and a recent overnight close placed it at $187.79, up 19.25%.

Source link